Psychedelic Therapy: A Primer for Primary Care Clinicians-The Strengths, Weaknesses, Opportunities, and Threats of Psychedelic Therapeutics.
Owen S. Muir, Kenneth Shinozuka, Bryce D. Beutler, Alejandro Arenas, Kirsten Cherian, Viviana D. Evans, Chelsey Fasano, Burton J. Tabaac
American Journal of Therapeutics DOI: 10.1097/MJT.0000000000001720 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Topics | Psychedelic-assisted therapy |
| Keywords | Psychedelics Mental health treatment Psychiatric medicine Drug research Therapeutic compounds |
| Citations | 5 |
| Key findings | Psychedelic compounds may offer more potent and rapidly acting treatments for psychiatric conditions compared to traditional small-molecule drugs, but only esketamine is currently FDA-approved for depression. |
Abstract
The reviews in this special edition have presented a primer on the state of the literature for 7 different psychedelic compounds and their plausible roles in medicine. In a common format underscoring strengths, weakness, opportunities, and threats (SWOT), this article addresses how psychedelic compounds fit into the broader health care landscape for indicated conditions. Historically, psychiatric pathologies have been treated with small-molecule compounds that have limited effect sizes and carry a variety of adverse effect profiles. Psychedelic medicines offer the opportunity to provide more potent and rapidly acting treatments. It is crucial to note that this is an emerging field of medicine, and only one of these compounds (esketamine) is currently Food and Drug Administration-approved for depression. The other compounds discussed are investigational, and this discussion is both imaginative and prospective in nature.
Comparable studies
Other narrative reviews on psychedelic-assisted therapy, most cited first.
Citations in the library
Cited by 5
- A Protocol for the Use of Psychedelics in Jungian Psychoanalysis 1 Journal of Analytical Psychology May 10, 2026
- Psychedelic Therapy: A Primer for Primary Care Clinicians—5-Methoxy-N,N-Dimethyltryptamine American Journal of Therapeutics February 20, 2026
- Examining the influence of team-based learning on medical students’ comprehension and attitudes regarding psychedelic therapies Dialogues in Clinical Neuroscience September 2, 2024
- Psychedelic Therapy: A Primer for Primary Care Clinicians-Mescaline. American Journal of Therapeutics
- Psychedelics Restructure the Global Workspace of Consciousness
Cites 29
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance Psychopharmacology July 7, 2006
- Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry May 17, 2016
- Trial of Psilocybin versus Escitalopram for Depression New England Journal of Medicine April 14, 2021
- Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder JAMA Psychiatry November 4, 2020
and 24 more in the library